Regulation of IncRNA PVT1 on miR-125 in metastasis of gastric cancer cells

JIATAI NIU¹, XIANGXIN SONG² and XIAOMEI ZHANG³

Departments of ¹Gastroenterology, ²Burn and Plastic Surgery, and ³Oncology, Jinan Zhangqiu District Hospital of TCM, Jinan, Shandong 250200, P.R. China

Received October 4, 2019; Accepted December 3, 2019

DOI: 10.3892/ol.2019.11195

Abstract. Regulation of long non-coding RNA (lncRNA) PVT1 on miR-125 affecting the metastasis of gastric cancer cells and the mechanism were investigated. qPCR was used to detect the expression of PVT1 and miR-125 in gastric cancer and paracancerous tissues, and the relationship between PVT1 and clinicopathological parameters of gastric cancer patients. Dual luciferase reporter gene was used to detect the mutual effect between PVT1 and miR-125. The clone formation assay was used to detect changes of proliferation behavior of gastric cancer cells after inhibition of PVT1. Transwell invasion assay was used to detect the changes of invasion ability of gastric cancer cells after inhibition of PVT1. Subcutaneous tumor formation in nude mice inhibited the effect of PVT1 on the tumor size and volume of gastric cancer cells. Compared with paracancerous tissues, the expression of PVT1 and miR-125 was significantly increased in gastric cancer tissues. There were no significant differences in the expression level of PVT1 between gastric cancer patients of different genders and ages. The higher the gastric cancer staging was, the more obvious the expression level of PVT1 in the tissues of patients with gastric cancer was, and the more obvious the expression of PVT1 in the tissues of patients with gastric lymph node metastasis was. PVT1 specifically bound to the 3'UTR of miR-125, whereas the inhibition of PVT1 inhibited the ability of proliferation and invasion of gastric cancer cells. In vitro experiment of tumor formation in nude mice showed that the tumor volume and weight of the tumor-bearing mice in the si-PVT1 group were significantly reduced. PVT1 plays an important role in the occurrence and development of gastric cancer, it can regulate the proliferation and invasion of gastric cancer cells by targeting miR-125 activity.

Introduction

Currently, gastric cancer is the fourth most common type of malignant tumor worldwide and the second leading cause of cancer-related deaths worldwide (1,2). Due to the lack of ideal biomarkers for early detection, ~80% of gastric cancer patients are diagnosed with advanced stage (3). Clinical treatment options of gastric cancer are limited because of its unclear pathophysiological mechanism (4,5). Therefore, identifying the molecular characteristics of gastric cancer and searching for new biomarkers are the main focus of current research on gastric cancer.

Long non-coding RNAs (lncRNAs) have been proven to be associated with the physiological and pathological processes of malignant tumors (6,7). IncRNA PVT1 is mainly found in the nucleus and mitochondria (8,9). It is highly expressed in a wide range of human tissues, which is crucial for the early development of embryogenesis (10). In mitochondria, IncRNA PVT1 helps endonuclease cut mitochondrial RNA at the priming site for mitochondrial DNA replication (11). In nucleoli, IncRNA PVT1 plays an important role in the final step of 5.8S rRNA processing (12). It can also form complexes and produce double-stranded RNA (dsRNA) through the interaction of reverse transcriptase catalytic subunit related to telomerase, which can be processed into small interfering RNA (siRNA) to play a corresponding biological role (13). With the knowledge above, however, the role of IncRNA PVT1 in the pathological process of tumors, especially in the process of carcinogenesis, remains unknown.

In recent years, increasing number of lncRNAs have been found with disorderly expression in gastric cancer (14-17). Our previous study also found IncRNA PVT1 disorderly expression in gastric cancer. In this study, in order to clarify the potential role of IncRNA PVT1 in gastric cancer and its clinical value, IncRNA PVT1 levels in tissues of patients with different stages of gastric cancer were detected and the role and molecular mechanism of IncRNA PVT1 in stomach neoplasms were studied.

Materials and methods

Tissue acquisition and cell culture. Gastric cancer and paracancerous tissues samples were obtained after informed consent of patients undergoing gastric cancer surgery in Jinan
Zhangqiu District Hospital of TCM (Jinan, China). The tumor and corresponding fresh non-tumor samples were rapidly frozen in liquid nitrogen and stored at -80°C immediately after excision to extract RNA and protein. This study was approved by the Ethics Committee of the Jinan Zhangqiu District Hospital of TCM. Gastric cancer BGC823 cells were grown in RPMI-1640 medium containing 10% fetal bovine serum. The cells were cultured at 37°C in a moist atmosphere containing 5% CO2.

Quantitative real-time polymerase chain reaction. TaqMan MicroRNA reverse transcription kit was used for reverse transcription to synthesize cDNA sense strand. RT-PCR was performed in Real-Time PCR system. Reaction conditions: Predegeneration at 95°C for 10 min, degeneration at 95°C for 15 sec, annealing at 60°C for 32 sec, the dissolution curve was detected after 50 cycles. After detection, Ct value of each sample was analyzed automatically through computer system, and then the relative expression of miRNA was calculate by 2^(-ΔΔCt). The experiment was repeated three times. PVT1 primer sequence, forward, 5'-CTGGAGAACGTGACACAGCAAACCT-3' and reverse, 5'-CCTATGGGCTACGGATGCGTCGCAAAGT-3'; miR-125 primer sequence, forward, 5'-TTGAGGAGGATGCTGGT AGGGCAAATTG-3' and reverse, 5'-GCCTACTATCGATGC ACAGGGGAGGCA-3'.

Dual luciferase determination. PVT1 fragments containing predicted wild-type (WT) or mutant type (MT) miR-125 in the binding sites were synthesized chemically, and dual luciferase miRNA targeted the downstream of the luciferase gene of the expression vector. The recombinant plasmids were termed as pmirGLO-miR-125-WT and pmirGLO-miR-125-MUT. Gastric cancer cells were cultured in 12-well plates, and then the recombinant plasmid was transfected with Lipofectamine 2000. The cells were harvested and cleaved after 24 h. Luciferase activity was determined using a dual-luciferase assay reporter system according to the manufacturer's instructions. The experiment was repeated three times.

Colony formation experiment. Lung cancer cells from different transfected groups were inoculated into the new 6-well plate (200 cells/well) at 5x10^4/well and cultured for ~2 weeks until colony formation could be observed. The cells were fixed in 4% paraformaldehyde and stained with crystal violet reagent to observe the number and condition of cell colony formation under a microscope.

Transwell invasion experiment. Cells (1x10^6) were suspended in 200 µl serum-free RPMI-1640 medium and inoculated into the upper chamber. In order to generate a chemical attractant environment in the lower chamber it was filled with RPMI-1640 supplemented with 20% FBS. After incubation in a cell incubator for 24 h, the cells on the top surface of the insert were removed. The cells on the bottom surface were fixed with 4% polyformaldehyde, and the number of invading cells was counted after staining with 0.1% crystal violet. The experiment was repeated three times.

Xenotransplantation model of nude mouse tumor. The cells in concentration of 1x10^6 in si-MALAT1 group and NC group were were injected into the armpits of nude mice aged 4-6 weeks, respectively. The volume and quality of tumor xenografts in nude mice were measured after 8 weeks. Allotransplant size was measured by the following formula: volume = 1/2 (minimum diameter) x (maximum diameter).

Statistical analysis. Spearman's Rank was used for correlation analysis, and Student's t-test was used for statistical analysis. The data were expressed as mean ± standard deviation, and the significance level was determined as P<0.05, which was considered to be statistically significant.

Results

Expression of PVT1 and miR-125 in gastric cancer tissues. The results of qPCR showed that: PVT1 mRNA expression level in gastric cancer tissues was significantly higher than that in paracancerous tissues [2.53±0.36 vs. 0.92±0.12, P<0.05] (Fig. 1). The expression level of miR-125 mRNA was significantly higher in gastric cancer tissues [1.28±0.17 vs. 0.43±0.15, P<0.05], and the differences were statistically significant. The expression levels of PVT1 and miR-125 were relatively high in gastric cancer.

Relationship between PVT1 and clinicopathological parameters of gastric cancer patients. In this study, 50 cases of gastric cancer tumor tissue samples and normal paracarcinoma tissues were statistically analyzed. There were no significant differences in the expression level of PVT1 between gastric cancer patients of different genders and age groups, with no statistical differences (P>0.05; Table I). The higher the stage of gastric cancer was, the more obvious the expression level of PVT1 in the tissues of patients with gastric cancer was, and the more obvious the expression of PVT1 in the tissues of patients with lymph node metastasis of gastric cancer was. Differences were statistically significant (P<0.05; Table I).

Correlation between PVT1 and miR-125 detected by dual luciferase assay. A relatively similar binding sequence between the two is shown in Fig. 2A, indicating a mutual regulation. The results of dual luciferase assay (Fig. 2B) showed that si-MALAT1 significantly inhibited the luciferase activity of miR-21, and regulated its expression activity and level.

Effect of PVT1 on proliferation of gastric cancer cells. The results of cell clone and proliferation experiments (Fig. 3) showed that the cell proliferation rate of the si-PVT1 experimental group was significantly lower than that of the control group [186.6±16.59 vs. 68.3±6.52, P<0.05]. The differences between the two groups were statistically significant.

Effect of PVT1 on invasion behavior of gastric cancer cells. The results of Transwell invasion showed that the number of cells in the si-PVT1 group passing through Matrigel was 181.52±13.24 (Fig. 4), which was significantly higher than that in the NC group (72.54±8.12), and the differences were statistically significant (P<0.05).

Effect of PVT1 on the growth of xenografts in nude mice. In order to study the effect of PVT1 in vivo, gastric cancer
cells infected with NC and si-PVT1 were injected into nude mice to observe the growth of xenografts. Compared with the NC group, the average tumor volume and weight of transplanted tumors in the si-PVT1 group decreased correspondingly [weight 182.63±19.32 vs. 31.32±6.25 mg, P<0.05; 212.32±21.32 vs. 40.65±6.08 mm, P<0.05] (P<0.05) (fig. 5), indicating that inhibition of PVT1 expression can also inhibit the growth of gastric cancer cells in vivo.

**Discussion**

lncRNAs play an important role in the occurrence and development of gastric cancer (18). In our previous studies, lncRNA PVT1 was found to be one of the most common disordered lncRNA in the expression profile of gastric cancer lncRNA (19). The purpose of this study was to investigate the molecular mechanism of lncRNA PVT1 in the occurrence of gastric cancer and to explore its diagnostic value. Tumorigenesis is a multi-step process (20). Gastric cancer is characterized by a phenotypic cascade of multistep progression (21). In this study, qRT-PCR was used to detect the differences in expression of lncRNA PVT1 between gastric cancer tissues and paired non-tumor tissues, and the results showed that lncRNA PVT1 level was upregulated in gastric cancer tissues. Then, the expression patterns were studied of lncRNA PVT1 in healthy gastric mucosa, gastric ulcer, erosive gastritis, gastric dysplasia and gastric cancer tissues. The results revealed that the expression of lncRNA PVT1 in gastric dysplasia and gastric cancer tissues was significantly increased. Downregulation of tissue specificity indicated that lncRNA PVT1 was strongly correlated with gastric cancer.

| Table I. Relationship between expression of PVT1 and clinicopathological features in tissues of patients with gastric cancer. |
|---------------------------------------------------------------|
| Clinicopathological data | Number | High expression of PVT1 | Low expression of PVT1 | P-value |
| Sex                  |        |                        |                        | 0.537   |
| Male                 | 30     | 17                      | 13                      |         |
| Female               | 20     | 8                       | 12                      |         |
| Age (years)          |        |                        |                        | 0.765   |
| ≤60                  | 29     | 18                      | 11                      |         |
| >60                  | 21     | 15                      | 6                       |         |
| Pathological staging |        |                        |                        | 0.019   |
| I                    | 9      | 1                       | 8                       |         |
| II                   | 13     | 5                       | 8                       |         |
| III                  | 19     | 5                       | 16                      |         |
| IV                   | 9      | 1                       | 7                       |         |
| Lymph node metastasis|        |                        |                        | 0.010   |
| No                   | 29     | 8                       | 21                      |         |
| Yes                  | 21     | 5                       | 16                      |         |

Figure 1. Expression of PVT1 and miR-125 in gastric cancer tissues. (A) Expression of PVT1 in gastric cancer tissues. (B) Expression of miR-125 in gastric cancer tissues. *P<0.05.
Body fluid is the main material for clinical diagnosis (22). The stability of humoral lncRNA is an important factor affecting its clinical application. Our results confirmed the stability of humoral lncRNA PVT1, which means that the properties of humoral lncRNA PVT1 meet the needs of routine clinical detection. The sensitivity and specificity of plasma or gastric juice RMRP serving as biomarkers for gastric cancer screening is the focus of this study. With convenient, painless and acceptable collection of plasma, gastric juice with high specificity to the stomach organs has a significant advantage in the detection of upper gastrointestinal tumors. In order to assess the clinical value of plasma and gastric juice lncRNA PVT1, we first analyzed the changes in plasma and gastric juice lncRNA PVT1 levels at each stage of gastric cancer. The results showed that the abnormal plasma lncRNA PVT1 level increased in patients in the gastric cancer group before operation but decreased rapidly after subtotal gastrectomy when compared with the healthy group. Gastric juice lncRNA PVT1 level increased significantly only in the gastric cancer group. These suggest that plasma and gastric juice lncRNA PVT1 can be used as biomarkers for gastric cancer screening, and postoperative plasma may be a prediction for the prognosis of patients with gastric cancer. Our data indicate that gastric juice has higher diagnostic value than plasma lncRNA PVT1.

In addition, age, tumor size, stage, invasion, lymphatic metastasis, perineural invasion and expression of CA19-9 are independent clinical prognostic factors in patients with gastric cancer (22). Tumor size, staging, and invasion are valuable predictors of cancer metastasis and survival (23), while perineural invasion and the presence of CA19-9, lymphatic metastasis, and age have been identified as independent prognostic factors (24). Previous studies have shown that the expression of lncRNA PVT1 in gastric cancer tissues is associated with these clinicopathological factors. Preoperative plasma lncRNA PVT1 level was negatively correlated with tumor diameter, staging, invasion and expression of tissue CEA, while the individual relative changes of plasma lncRNA PVT1 level 2 weeks after surgery were significantly negatively correlated with lymph node metastasis and expression of tissue CEA. These results suggest that lncRNA PVT1 is also a potential biomarker for predicting the prognosis of gastric cancer.

The balance between cell proliferation and apoptosis depends on the regulation of oncogenes, anticancer genes.
and growth factors (25). In this study, it was found that the changes of lncRNA PVT1 expression in gastric cells had significant effects on cell proliferation in vitro and in vivo, and the role of proliferation was correlated with the cell cycle. Recent studies support that some lncRNAs, such as FER1L4, CCAT1 and SNAI1, played an important role in the regulation of gene expression by acting as miRNA sponges (26). We identified that lncRNA PVT1 contains a seed sequence that may bind to six miRNAs and then confirmed that only miR-125 is closely related to gastric cancer in these miRNAs.

In conclusion, the in vivo and in vitro mechanisms studied suggest that lncRNA PVT1 plays a crucial role in the occurrence and development of gastric cancer. Moreover, lncRNA PVT1 may inhibit the proliferation and invasion of gastric cancer cells by regulating the expression of miR-125, which may be a potential biomarker for screening and predicting the prognosis of gastric cancer.

Acknowledgements

Not applicable.
Funding

No funding was received.

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors' contributions

JN and XZ conceived and designed the study. JN, XS and XZ were responsible for the collection, analysis and interpretation of the data. JN drafted the manuscript. JN revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The study was approved by the Ethics Committee of Jinan Ethics approval and consent to participate read and approved the final manuscript.

Authors' contributions

JN and XZ conceived and designed the study. JN, XS and XZ were responsible for the collection, analysis and interpretation of the data. JN drafted the manuscript. JN revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Plummer M, Franceschi S, Vignat J, Forman D and de Martel C: Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer 136: 487-490, 2015.
2. Anderson WF, Rabkin CS, Turner N, Fraumeni JF Jr, Rosenberg PS and Camargo MC: The changing face of noncardia gastric cancer incidence among US non-hispanic whites. J Natl Cancer Inst 110: 608-615, 2018.
3. Moscetti S, Verdi D, Pooley KA and Nitti D: Genetic variation and gastric cancer risk: A field synopsis and meta-analysis. Gut 64: 1209-1219, 2015.
4. Huang Z, Zhu D, Wu L, He M, Zhou X, Zhang L, Zhang H, Wang W, Zhu J, Cheng W, et al: Six serum-based miRNAs as potential diagnostic biomarkers for gastric cancer. Cancer Epidemiol Biomarkers Prev 26: 188-196, 2017.
5. Ma J, Shen H, Kapesa L and Zeng S: Lauren classification and individualized chemotherapy in gastric cancer. Oncol Lett 11: 2959-2964, 2016.
6. Xue X, Yang YA, Zhang A, Fong KW, Kim J, Song B, Li S, Zhao J and Yu J: LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer. Oncogene 35: 2746-2755, 2016.
7. Sun M, Nie F, Wang Y, Zhang Z, Hou J, He D, Xie M, Xu L, De W, Wang Z, et al: LncRNA HOXA11-AS promotes proliferation and invasion of gastric cancer by scaffolding the chromatin modification factors PRCC, LSD1, and DNMT1. Cancer Res 76: 6299-6310, 2016.
8. Huang C, Yu W, Wang Q, Cui H, Wang Y, Zhang L, Han F and Huang T: Increased expression of the IncRNA PVT1 is associated with poor prognosis in pancreatic cancer patients. Minerva Med 106: 143-149, 2015.
9. Zhao L, Kong H, Sun H, Chen Z, Chen B and Zhou M: LncRNA-PVT1 promotes pancreatic cancer cells proliferation and migration through acting as a molecular sponge to regulate miR-448. J Cell Physiol 233: 4044-4055, 2018.
10. Liu HT, Fang L, Cheng YX and Sun Q: LncRNA PVT1 regulates prostate cancer cell growth by inducing the methylation of miR-146a. Cancer Med 5: 3512-3519, 2016.
11. Yu J, Han J, Zhang J, Li G, Liu H, Cui X, Xu Y, Li T, Liu J and Wang C: The long noncoding RNAs PVT1 and uc002mbc.2 in sera provide a new supplementary method for hepatocellular carcinoma diagnosis. Medicine (Baltimore) 95: e4346, 2016.
12. Yoshida K, Todsen S, Ravindranathan P, Han H and Goel A: Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the IncRNA PVT1 expression. Carcinogenesis 38: 1036-1046, 2017.
13. Zhao J, Du P, Cui P, Qin Y, Hu C, Wu J, Zhou Z, Zhang W, Qin L and Huang G: LncRNA PVT1 promotes angiogenesis via activating the STAT3/VEGFA axis in gastric cancer. Oncogene 37: 4094-4109, 2018.
14. Liu Z, Chen Z, Fan R, Jiang B, Chen X, Chen Q, Nie F, Lu K and Sun M: Over-expressed long noncoding RNA HOXA11-AS promotes cell cycle progression and metastasis in gastric cancer. Mol Cancer 16: 82, 2017.
15. Shi SJ, Wang LJ, Yu B, Li YH, Jin Y and Bai XZ: LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer. Oncotarget 6: 11652-11663, 2015.
16. Zhou M, Hou Y, Yang G, Zhang H, Tu G, Du YE, Wen S, Xu L, Tang X, Tang S, et al: LncRNA-Hh strengthens cancer stem cells generation in twist-positive breast cancer via activation of Hedgehog signaling pathway. Stem Cells 34: 55-66, 2016.
17. Zhou M, Sun Y, Sun Y, Xu W, Zhang Z, Zhao H, Zhong Z and Sun J: Comprehensive analysis of IncRNA expression profiles reveals a novel IncRNA signature to discriminate nonequivalent outcomes in patients with ovarian cancer. Oncotarget 7: 32433-32448, 2016.
18. Niknafs YS, Han S, Ma T, Speakers C, Zhang C, Wilder-Roman M, Iyer MK, Pitchiaya S, Malik R, Hosono Y, et al: The IncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. Nat Commun 7: 12791, 2016.
19. Huang T, Liu HW, Chen JQ, Wang SH, Hao LQ, Liu M and Wang B: The long noncoding RNA PVT1 functions as a competing endogenous RNA by sponging miR-186 in gastric cancer. Biomed Pharmacother 88: 302-308, 2017.
20. Shen CJ, Cheng YM and Wang CL: LncRNA PVT1 epigenetically silences miR-195 and modulates EMT and chemoresistance in cervical cancer cells. J Drug Target 25: 637-644, 2017.
21. Wan L, Sun M, Liu GJ, Wei CC, Zhang EB, Kong R, Xu TP, Huang MD and Wang ZX: Long noncoding RNA PVT1 promotes non-small cell lung cancer cell proliferation through epigenetically regulating LATS2 expression. Mol Cancer Ther 15: 1082-1094, 2016.
22. Warner ET, Tamimi RM, Hughes ME, Oilsea EA, Wong YN, Edge SB, Theriault RL, Blayney DW, Niland JC, Winer EP, et al: Ethnic and racial differences in breast cancer survival: Mediating effect of tumor characteristics and socioeconomic and treatment factors. J Clin Oncol 33: 2254-2261, 2015.
23. Krammer J, Pinker-Domenig K, Rohson ME, Gönen M, Bernard-Davila B, Morris EA, Mangino DA and Jochelson MS: Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 163: 565-571, 2017.
24. Miglioretti DL, Zhu W, Kerlikowske K, Sprague BL, Onega T, Buist DS, Henderson LM and Smith RA; Breast Cancer Surveillance Consortium: Breast tumor prognostic characteristics and biennial vs annual mammography, age, and menopausal status. JAMA Oncol 1: 1069-1077, 2015.
25. Ma MZ, Zhu BF, Zhang Y, Weng MZ, Qin YY, Gong W and Quan ZW: Long non-coding RNA CCAT1 promotes gallbladder cancer development via negative modulation of miRNA-218-Sp. Cell Death Dis 6: e1583, 2015.
26. Madhavan B, Yue S, Galli U, Rana S, Gross W, Müller M, Giese NA, Kalthoff H, Becker T, Büchler MW, et al: Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity. Int J Cancer 136: 2616-2627, 2015.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.